结构多样化的小分子的生物物理和生物化学表征对KRAS抑制产生了影响
Cynthia V Pagba1, Amit K Gupta1, Kasuni Dilsha2
1Department of Integrative Biology and Pharmacology, McGovern Medical School, The University of Texas Health Science Center at Houston, 6431 Fannin St., Houston, Texas, 77030, USA.
Chembiochem : a European journal of chemical biology
|February 13, 2024
概括
研究人员确定了六种新型化合物作为开发直接KRAS抑制剂的早期打击. 这些化合物通过调节其信号通路,在癌症治疗中具有向KRAS蛋白的潜力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 由于其在各种癌症中的作用,KRAS是抗癌药物开发的关键目标.
- 对于治疗干预来说,KRAS的直接抑制剂非常受欢迎.
研究的目的:
- 识别和描述早期阶段化合物作为KRAS的直接抑制剂.
- 评估这些新型化合物对KRAS的结合亲缘关系和功能影响.
主要方法:
- 对针对KRAS的六个打击化合物的选和描述.
- 对化合物与KRAS的结合 afinities 的评估.
- 对KRAS激活,信号通路 (MAPK,PI3K/AKT) 和RAS效应因子相互作用的化合物效应的评估.
主要成果:
- 六种化合物被确定为早期的热点,具有较低的微分子结合亲缘关系到KRAS.
- 这些化合物表现出多种作用,包括选择性结合激活的KRAS和抑制MAPK和PI3K/AKT信号传递.
- 对不同化合物观察到KRAS激活和RAS-effector相互作用的抑制.
结论:
- 这些已识别的化合物代表了开发非共价性全性KRAS抑制剂的有希望的起点.
- 这些抑制剂具有针对性癌症治疗的潜力,特别是在KRAS突变癌症中.
相关概念视频
01:28Structure-Activity Relationships and Drug Design
721
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
721
01:24Small GTPases - Ras and Rho
4.0K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
4.0K